Published in Cancer Weekly, December 24th, 2002
Mitozytrex becomes the first approved drug based on SuperGen's patented 'supergenerics' Extra technology platform.
"We are very pleased to have received FDA clearance to market Mitozytrex. This approval marks a milestone as it is the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.